scispace - formally typeset
A

Alessia Grozio

Researcher at University of Genoa

Publications -  40
Citations -  2316

Alessia Grozio is an academic researcher from University of Genoa. The author has contributed to research in topics: NAD+ kinase & Nicotinamide mononucleotide. The author has an hindex of 19, co-authored 38 publications receiving 1521 citations. Previous affiliations of Alessia Grozio include National Cancer Research Institute & Washington University in St. Louis.

Papers
More filters
Journal ArticleDOI

Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice.

TL;DR: NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorated eye function and other pathophysiologies and highlighted the preventive and therapeutic potential of NAD+ intermediates as effective anti-aging interventions in humans.
Journal ArticleDOI

NAD+ metabolism and its roles in cellular processes during ageing

TL;DR: Nicotinamide adenine dinucleotide (NAD+) is a coenzyme for redox reactions, making it central to energy metabolism and is also an essential cofactor for non-redox NAD+-dependent enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases as discussed by the authors.
Journal ArticleDOI

Slc12a8 is a nicotinamide mononucleotide transporter

TL;DR: A specific NMN transporter is discovered, encoded by the Slc12a8 gene, which regulates NMN uptake and cellular NAD+ levels in vitro and in the mouse intestine in vivo, and demonstrates that Slc 12a8 has a critical role in regulating intestinal NAD+ metabolism.
Journal ArticleDOI

CD73 Protein as a Source of Extracellular Precursors for Sustained NAD+ Biosynthesis in FK866-treated Tumor Cells

TL;DR: It is demonstrated that low micromolar concentrations of extracellular NAD+ or NAD+ precursors, nicotinamide mononucleotide (NMN) and NR, can reverse the FK866-induced cell death, this representing a plausible explanation for the failure of NAMPT inhibition as an anti-cancer therapy.